NASDAQ : HURA
TuHURA Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 122.99M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 122.99M |
| Enterprise Value | 131.18M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 63.73M |
| Shares Outstanding | 63.73M |
| Shares Change (YoY) | +60.94% |
| Shares Change (QoQ) | +6.59% |
| Owned by Insiders (%) | 36.30% |
| Owned by Institutions (%) | 14.31% |
| Float | 39.70M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.75 |
| P/TBV Ratio | 16.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.18 |
| Quick Ratio | 0.14 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.68 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -161.39% |
| Return on Assets (ROA) | -58.43% |
| Return on Invested Capital (ROIC) | -81.32% |
| Return on Capital Employed (ROCE) | -137.93% |
| Weighted Average Cost of Capital (WACC) | 0.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.39M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.84 |
| 52-Week Price Change | -21.22% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 1.97 |
| Relative Strength Index (RSI) | 47.47 |
| Average Volume (20 Days) | 365,309 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.94M |
| Short Previous Month | 6.10M |
| Short % of Shares Out | 9.32% |
| Short % of Float | 14.96% |
| Short Ratio (days to cover) | 27.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -31.02M |
| Pretax Income | -30.62M |
| Net Income | -30.63M |
| EBITDA | -30.93M |
| EBIT | -31.02M |
| Earnings Per Share (EPS) | -$0.54 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 995,977 |
| Total Debt | 9.18M |
| Net Cash | -8.18M |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | 18.50M |
| Book Value Per Share | 0.29 |
| Working Capital | -7.60M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -29.69M |
| Capital Expenditures | -213,674 |
| Depreciation & Amortization | 95,412 |
| Net Borrowing | 4.00M |
| Free Cash Flow | -29.90M |
| FCF Per Share | -$0.47 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -60.94% |
| Shareholder Yield | -60.94% |
| Earnings Yield | -28.12% |
| FCF Yield | -24.31% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.04 |
| Price Target Difference | 316.58% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |